The protest happened roughly 27 minutes into the meeting, held at NIH headquarters in Bethesda, Md. In a video obtained by CNN, Bhattacharya is shown telling staff that, based on his review of ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

The approval for interchangeability was supported by data from a phase 4 trial that assessed the pharmacokinetics, efficacy, safety, and immunogenicity of Hadlima vs Humira in patients with moderate ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.